Alterity Therapeutics Limited
ATHE
$4.60
-$0.10-2.13%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 32.42% | 20.90% | 7.90% | 4.55% | 0.07% |
| Total Revenue | 32.42% | 20.90% | 7.90% | 4.55% | 0.07% |
| Cost of Revenue | -41.25% | -29.85% | -19.28% | -22.87% | -26.69% |
| Gross Profit | 36.57% | 24.07% | 9.80% | 6.59% | 2.17% |
| SG&A Expenses | 14.04% | 26.37% | 39.52% | 14.81% | -7.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1,567.65% | 1,028.57% | 666.00% | 72.95% | -82.74% |
| Total Operating Expenses | -16.26% | 10.10% | 47.73% | 36.20% | 24.25% |
| Operating Income | 26.23% | -7.62% | -58.32% | -44.65% | -30.72% |
| Income Before Tax | 37.32% | -1.05% | -59.65% | -48.15% | -35.86% |
| Income Tax Expenses | 41.78% | 137.01% | 7,500.00% | -12.14% | -56.63% |
| Earnings from Continuing Operations | 37.13% | -1.26% | -60.01% | -47.91% | -35.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.13% | -1.26% | -60.01% | -47.91% | -35.16% |
| EBIT | 26.23% | -7.62% | -58.32% | -44.65% | -30.72% |
| EBITDA | 26.24% | -7.67% | -58.52% | -44.79% | -30.82% |
| EPS Basic | 62.86% | 41.18% | 18.18% | 13.89% | 7.89% |
| Normalized Basic EPS | 50.00% | 35.00% | 20.00% | 18.18% | 16.67% |
| EPS Diluted | 60.00% | 38.24% | 15.15% | 13.89% | 7.89% |
| Normalized Diluted EPS | 50.00% | 35.00% | 20.00% | 18.18% | 16.67% |
| Average Basic Shares Outstanding | 75.31% | 87.04% | 104.33% | 77.56% | 50.29% |
| Average Diluted Shares Outstanding | 75.31% | 87.04% | 104.33% | 77.56% | 50.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |